Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19



Rating:

Share or cite this content

Citations should be made in the following way:
P. Kamstrup (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark), J. Eklöf (Hellerup, Denmark), N. Hoyer (Hellerup, Denmark), C. Ulrik (Hvidovre, Denmark), L. Pedersen (Copenhagen, Denmark), T. Lapperre (Copenhagen, Denmark), Z. Harboe (Hilleroed, Denmark), U. Bodtger (Naestved, Denmark), R. Bojesen (Slagelse, Denmark), K. Håkansson (Hvidovre, Denmark), C. Tidemandsen (Hvidovre, Denmark), K. Armbruster (Hellerup, Denmark), A. Browatzki (Hilleroed, Denmark), H. Meteran (Hellerup, Denmark), C. Meyer (Roskilde, Denmark), K. Skaarup (Hellerup, Denmark), M. Lassen (Hellerup, Denmark), J. Lundgren (Copenhagen, Denmark), T. Biering-Sørensen (Hellerup, Denmark), J. Jensen (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark). Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection. 923

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Source: Eur Respir J 2006; 28: Suppl. 50, 128s Year: 2006 Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART Source: Breathe 2008; 5: 274 Year: 2009 Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 What happens to pneumocystis prophylaxis use when antiretroviral therapy is widely available? Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Secondary drug resistance during an intravenous intermittent chemotherapy in newly cases TB Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 The efficacy of antiviral therapy of acute respiratory infections in paediatric practice Source: International Congress 2017 – New insights into paediatric respiratory infections Year: 2017 The use of antiviral drug Ribavirin in cases of viral-bacterial community acquired pneumonia Source: International Congress 2018 – Pleural diseases and pneumonia: what's new ? Year: 2018 Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Prophylaxis with azithromycin in primary immunodeficiency and bronchiectasis Source: Annual Congress 2005 - New insights in respiratory infections in children Year: 2005 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 569-571 Year: 2015 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 571-574 Year: 2015 Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020 Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016